Post-earnings recap
Reported
Tue, Oct 29, 2024
EPS actual
$-0.18
EPS est.
$-0.01
EPS surprise
-1284.62%
1-day move
-15.68%
Est. EPS
—
Est. Rev
—
Impl. Move
—
Kiniksa Pharmaceuticals reported a larger-than-expected loss per share, which contributed to a significant drop in stock price. The lack of revenue data and guidance left investors uncertain about the company's future performance. The stock's decline reflects investor concerns over the company's ability to meet financial expectations going forward.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.18 | N/A | -1284.62% |
| Revenue | N/A | N/A | N/A |
Management expressed concerns about the current financial performance. They did not provide specific guidance for future quarters.
Management did not provide specific insights into revenue performance.
The company acknowledged challenges in meeting expectations.